“In an advance, online publication of Science this week, investigators [Dr KJ Patel] at the MRC Laboratory of Molecular Biology in Cambridge, UK, and their colleagues report that the “disruption of both FANCC and [nonhomologous end joining factor] Ku70 suppresses sensitivity to cross-linking agents, diminishes chromosome breaks, and reverses defective homologous recombination” in Fanconi anemia.” […]
This Week in Science
Video interviews of ERBI conference
“This is a series of brief film interviews with entrepreneurs, scientists and company executives from the ERBI region [including Dr Richard Henderson and Sir Gregory Winter from LMB] speaking about a wide range of topical issues such as their careers or their involvement in the biotechnology industry”.
Jason Chin wins 2010 RSC Corday-Morgan Prize
Jason Chin has won the Royal Society of Chemistry’s 2010 Corday-Morgan Prize. The award was made in recognition of Jason’s “pioneering work on genetically encoding the synthesis of novel polymers in cells through development of methods to incorporate, for example, new amino acids”. The Corday-Morgan Prize is a prestigious award that has been made annually […]
Geoffrey Grigg Traveling Fellowship established between LMB and the Garvan Institute
LMB and the Garvan Institute, Sydney, Australia have set up the Geoffrey Grigg Traveling Fellowship aimed at enabling short scientific exchange visits between the two institutions. The Fellowship commemorates Geoffrey Grigg, who was an Australian scientist, highly influential in the fields of genetics, molecular biology and DNA research and a pioneer of Australia’s biotechnology industry. […]
Michael Hastings elected Fellow of the Royal Society
Dr Michael Hastings, group leader in LMB’s Neurobiology Division, has been elected as a Fellow of the Royal Society. Michael is distinguished for his highly influential contributions to our understanding of biological clocks through the study of the suprachiasmatic nucleus (SCN) of the hypothalamus in the brain. He was instrumental in unravelling the controls on […]
Heptares Therapeutics extends multi-fte chemistry collaboration with oxygen healthcare (o2h)
“Executives from Heptares Therapeutics (Welwyn Garden City, UK) and O2h (Cambridge, UK) announced today an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares… Heptares is a drug discovery company focused on identifying novel drug candidates targeting validated G-protein-coupled receptors (GPCRs) in several disease areas. Heptares […]